Vendor review
Tianjin Eleli Technology Development reviews
Tianjin Eleli Technology Development reviews from 47 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Tianjin Eleli Technology Development legit? See what its vials showed.
What the lab tests show
47 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 6, 2026 | Retatrutide | 99.9 % | 18.4 mg of 20 mg (-8 %) | Pass | View |
| Sep 25, 2026 | Cagrilintide | 5 mg | Fail | View | |
| Sep 25, 2026 | Tirzepatide | 99.9 % | 30.6 mg of 30 mg (2 %) | Pass | View |
| Sep 25, 2026 | GHK-Cu | 99.4 % | 43.9 mg of 100 mg (-56 %) | Pass | View |
| Sep 24, 2026 | TB-500 | 10 mg | Fail | View | |
| Sep 18, 2026 | Tirzepatide | 99.99 % | 16.86 mg of 20 mg (-16 %) | Pass | View |
| Sep 18, 2026 | BPC-157 | 99.99 % | 9.46 mg of 10 mg (-5 %) | Pass | View |
| Aug 13, 2026 | TB-500 | 10 mg | Fail | View | |
| Aug 12, 2026 | BPC-157 | 92.2 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Aug 12, 2026 | GHK-Cu | 79.3 % | 12.3 mg of 50 mg (-75 %) | Pass | View |
| Aug 9, 2026 | Retatrutide | 99.8 % | 20.8 mg of 20 mg (4 %) | Pass | View |
| Aug 9, 2026 | Tirzepatide | 30 mg | Fail | View | |
| Aug 9, 2026 | BPC-157 | 99.7 % | 13.6 mg of 10 mg (36 %) | Pass | View |
| Jul 15, 2026 | Tesamorelin | 10 mg | Fail | View | |
| Jul 13, 2026 | Retatrutide | 99.8 % | 20.7 mg of 20 mg (3 %) | Pass | View |
| Jun 26, 2026 | Retatrutide | 30 mg | Fail | View | |
| Jun 26, 2026 | Retatrutide | 99.6 % | 19.1 mg of 20 mg (-4 %) | Pass | View |
| Jun 26, 2026 | Tirzepatide | 30 mg | Fail | View | |
| Jun 24, 2026 | Retatrutide | 99.9 % | 9.27 mg of 10 mg (-7 %) | Pass | View |
| Jun 24, 2026 | GHK-Cu | 99.6 % | 89.2 mg of 100 mg (-11 %) | Pass | View |
| Jun 15, 2026 | Retatrutide | 99.9 % | 9.36 mg of 10 mg (-6 %) | Pass | View |
| Jun 15, 2026 | GHK-Cu | 99.9 % | 13.3 mg of 50 mg (-73 %) | Pass | View |
| Jun 15, 2026 | Retatrutide | 40 mg | Fail | View | |
| Jun 6, 2026 | Retatrutide | 99.8 % | 22 mg of 20 mg (10 %) | Pass | View |
| May 8, 2026 | Retatrutide | 99.9 % | 28.7 mg of 30 mg (-4 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 98.9 % | 9.83 mg of 10 mg (-2 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 28.3 mg of 30 mg (-6 %) | Pass | View |
| Mar 25, 2026 | Retatrutide | 99.9 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| Mar 21, 2026 | BPC-157 | 99.8 % | 12.4 mg of 10 mg (24 %) | Pass | View |
| Mar 18, 2026 | Tesamorelin | 99.9 % | 9.23 mg of 10 mg (-8 %) | Pass | View |
| Mar 18, 2026 | GHK-Cu | 99.9 % | 94.3 mg of 50 mg (89 %) | Pass | View |
| Mar 4, 2026 | Tirzepatide | 98.11 % | 29.7 mg of 30 mg (-1 %) | Pass | View |
| Mar 4, 2026 | Tirzepatide | 99.19 % | 44.8 mg of 30 mg (49 %) | Pass | View |
| Mar 3, 2026 | Retatrutide | 99.67 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Mar 3, 2026 | Retatrutide | 30 mg | Fail | View | |
| Feb 22, 2026 | GHK-Cu | 99.9 % | 61.9 mg of 100 mg (-38 %) | Pass | View |
| Feb 20, 2026 | Cagrilintide | 98.5 % | 4.66 mg of 5 mg (-7 %) | Pass | View |
| Feb 11, 2026 | BPC-157 | 99.9 % | 8.56 mg of 10 mg (-14 %) | Pass | View |
| Feb 11, 2026 | GHK-Cu | 99.9 % | 82.7 mg of 100 mg (-17 %) | Pass | View |
| Feb 11, 2026 | Tirzepatide | 99.9 % | 42.3 mg of 40 mg (6 %) | Pass | View |
| Feb 10, 2026 | BPC-157 | 99.8 % | 11.6 mg of 10 mg (16 %) | Pass | View |
| Feb 10, 2026 | Retatrutide | 99.8 % | 21.9 mg of 20 mg (10 %) | Pass | View |
| Feb 8, 2026 | Tesamorelin | 99.9 % | 9.5 mg of 10 mg (-5 %) | Pass | View |
| Feb 6, 2026 | TB-500 | 99.9 % | 4.92 mg of 5 mg (-2 %) | Pass | View |
| Feb 4, 2026 | Retatrutide | 98.6 % | 9 mg of 10 mg (-10 %) | Pass | View |
| Jan 29, 2026 | Tirzepatide | 30 mg | Fail | View | |
| Jan 26, 2026 | Retatrutide | 99.8 % | 15.2 mg of 15 mg (1 %) | Pass | View |
What Tianjin Eleli Technology Development sells
No current listings on record.
About Tianjin Eleli Technology Development
Finnrick has tested 47 samples from Tianjin Eleli Technology Development across 7 products.